# APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

> **NCT06634394** · PHASE1 · RECRUITING · sponsor: **Aptevo Therapeutics** · enrollment: 39 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** APVO436
- **DRUG:** Venetoclax
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT06634394
- **Lead sponsor:** Aptevo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2027-10
- **Final completion:** 2028-03
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06634394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06634394, "APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT06634394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*